tumor necrosis factor receptor type i, p55 soluble fragment Report issue

Biologics Recombinant protein Experimental
AACT ChEMBL MeSH

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

glycoprotein tnf-bp (tumor necrosis factor-binding protein) (human disulfide variant 1) | onercept | peg-linked dimeric form of rstnf-ri | peg-linked dimeric type i soluble receptor of tnf | peg-(rstnf-ri)2 | receptor(55), tnf | recombinant human soluble p55 tumour necrosis factor receptor | recombinant human tumor necrosis factor-binding protein-1 | r-htbp-1 | tnf receptor p55 | tnfrp55 | tnf-sr55 | tumor necrosis factor receptor 55 | tumor necrosis factor receptor type i, p55 soluble fragment

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Arthritis, Psoriatic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue